CTOs on the Move

Atmofizer

www.atmofizer.com

 
The world’s most innovative and effective clean air technology against harmful ultra fine particles incl. COVID-19. Developed in Germany, assembled in the US.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.atmofizer.com
  • 1680, Michigan Avenue
    Miami Beach, FL USA 33139
  • Phone: 727.440.8270

Executives

Name Title Contact Details

Similar Companies

Swift Biosciences

Swift Biosciences is a biotechnology company that is developing novel molecular biology technologies to better characterize and understand the genome. We are an energetic, highly innovative company focused on creating tools to advance the DNA sequencing sciences. Our products are designed to help customers analyze challenging samples that are often associated with translational work, including circulating, cell-free DNA and formalin-fixed, paraffin-embedded samples.

Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.

Avicanna

Avicanna is a diversified and vertically integrated Canadian bio-pharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments. Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna`s team of experts have developed and commercialized several industry leading product lines, including: Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and, RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data. With ongoing clinical trials on its medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna`s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company`s vision since its inception. Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp derived API and custom formulations.

Powerpollen

PowerPollen offers a breakthrough, scalable technology to collect, preserve and apply pollen on-demand to help improve the productivity, profitability and sustainability of modern farming practices.

Carmot Therapeutics

Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot`s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.